Preliminary Results for the year ending 31 December 2020
Avacta Group PLC (AVCT.L) Final Results
Avacta Group PLC (AVCT.L) Clinical validation of AffiDX ® SARS-CoV-2 Antigen Lateral Flow Test
98.0% clinical sensitivity for samples with PCR Ct values [1] up to 31
4d Pharma PLC (DDDD.L) Participation in Jefferies Therapeutics Summit
4D pharma to Participate in Jefferies Microbiome-Based Therapeutics Summit
Destiny Pharma PLC (DEST.L) to Join Equity Development Webinar
Destiny Pharma to Join Equity Development Webinar on Positive Phase 2b Top-line Results for XF-73 Nasal Gel
Avacta Group PLC (AVCT.L) Directorate Change
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announces that the Dr Mike Owen has stepped down
Avacta Group PLC (AVCT.L) Rapid Antigen Test Detects SARS-CoV-2 Variants
Avacta’s AffiDX® SARS-CoV-2 lateral flow test detects both B117 ‘Kent’ and D614G variants of the virus
Avacta Group PLC (AVCT.L) Significant momentum in both Diagnostics and Therapeutics Divisions
AffiDX®, SARS-CoV-2 Lateral Flow Rapid Antigen Test generates excellent initial clinical sensitivity and specificity data MHRA approves Clinical Trial Authorisation of first therapeutic product candidate
Avacta Group PLC (AVCT.L) Re: Press Speculation
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, notes the recent press speculation about UK Government take-up of Avacta’s lateral flow SARS-CoV-2 rapid antigen test.
Avacta Group PLC (AVCT.L) Commercial Partnership with Mologic
Partnership to accelerate CE marking of Avacta’s SARS-CoV-2 rapid antigen test and support COVID-19 testing in low and middle income countries
Avacta Group PLC (AVCT.L) License Agreement with POINT Biopharma Inc.
License to utilise Avacta’s pre|CISIONTM FAP sensitive activation platform for radiopharmaceuticals
Avacta Group PLC (AVCT.L) SARS-CoV-2 Rapid Antigen Test Update
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISIONTM platforms, is pleased to announce significant progress in the development
